Translate this page to:
In JoVE (1)
- Пептидов из библиотеки Показать Фаг Модуляция экспрессии генов в клетки и мезенхимальные Потенцирует остеогенез в Unicortical костных дефектов
Other Publications (4)
This translation into Russian was automatically generated.
English Version | Other Languages
Articles by Haixiang Liang in JoVE
Пептидов из библиотеки Показать Фаг Модуляция экспрессии генов в клетки и мезенхимальные Потенцирует остеогенез в Unicortical костных дефектов
Gary Balian1, Gina Beck1, Vedavathi Madhu1, Robert Sikes2, Quanjun Cui3, Haixiang Liang1, Joshua Bush1
1Orthopaedics Research, University of Virginia, 2Biological Sciences, University of Delaware, 3Orthopaedic Surgery, University of Virginia
Библиотека фагового дисплея была использована для определения пептидных последовательностей, предназначенных для костей. Целью было изучение влияния этих пептидов на мезенхимальной дифференциации клеток и определить их влияние на регенерацию кости.
Other articles by Haixiang Liang on PubMed
Therapeutic Effects of Adenovirus-mediated Growth and Differentiation Factor-5 in a Mice Disc Degeneration Model Induced by Annulus Needle Puncture
The Spine Journal : Official Journal of the North American Spine Society. Jan, 2010 | Pubmed ID: 19926342
The therapeutic strategies that have thus far been used for the treatment of intervertebral disc degeneration (IDD) have focused on relieving the symptoms, although reversal of the degeneration remains an important challenge for the effective treatment of IDD. Growth and differentiation factor-5 (GDF5), of which deficiency leads to early disc degeneration changes, has the potential to increase proliferation of disc cells and expression of extracellular matrix proteins.
Use of a Bioactive Scaffold for the Repair of Bone Defects in a Novel Reproducible Vertebral Body Defect Model
Bone. Aug, 2010 | Pubmed ID: 20580872
Bone defects in vertebral bodies (VB) usually occur after the reduction of fractures or are caused by bone disease. Besides the treatment of original disease, repair of the bone defect can restore the structure of VB and improve stabilization of the spine to protect the spinal cord nerves. To aid studies of the efficacy of bioengineering techniques for repair of VB, we developed a rat model with a critical size bone defect in VB. Air-motivated burrs were used to create two sizes of bone defect (2 x 3 x 1.5 mm; 2 x 3 x 3 mm) in the anterior part of VB in 6-month-old Fischer 344 rats. Quantitative CT analyses and histological assays demonstrated that neither defects self-repaired by 8 weeks post surgery. Moreover, the tendency of bone formation was monitored in the same animal by serial CT image evaluations, allowing us to demonstrate that there was significant bone growth during the 4- to 6-week period after the creation of the bone defect. We then implanted sintered poly(lactic-co-glycolic acid) (PLGA) microsphere scaffolds loaded with Matrigel with or without recombinant human bone morphogenetic protein 2 (rhBMP2; 2.0 microg rhBMP2/10 microL Matrigel/scaffold) into the bone defect (2 x 3 x 3 mm) in the VB. Bone formation was detected by quantitative analyses of serial CT images, which demonstrated bone growth in rats that received the rhBMP2 implant, in both surrounding areas and inside area of the scaffold. In addition to a rapid increase within 2 weeks of the operation, another significant bone formation period was found between 4 and 8 weeks after the implantation. By contrast, the control group that received the implant without rhBMP2 did not show similar bone formation tendencies. The results of CT analyses were confirmed by histological studies. This study suggests that a critical size bone defect of the anterior VB can be developed in a rat model. Characterization of this model demonstrated that 4 to 6 weeks after creation of the defect was a significant bone growth period for VB bone repair in rats. This animal model has further utility for the study of different biomaterials for VB bone repair. Implantation of a bioactive PLGA scaffold carrying rhBMP2 allowed more successful repair of the VB defect. Although further characterization studies are needed, the bioactive PLGA scaffold developed in this study will likely adapt easily to other in vivo osteogenesis applications.
The Reaction of Bone to Tumor Growth from Human Breast Cancer Cells in a Rat Spine Single Metastasis Model
Spine. Apr, 2011 | Pubmed ID: 21422981
In vivo experiments to develop a rat spine single metastasis model by using human breast cancer cells.
Journal of the American Association for Laboratory Animal Science : JAALAS. Mar, 2011 | Pubmed ID: 21439213
Preventing and minimizing pain in laboratory animals is a basic tenet of biomedical research and is warranted for ethical, legal, and scientific reasons. Postoperative analgesia is an important facet of pain management. A sustained-release formulation of buprenorphine was tested in rats for analgesic efficacy and plasma concentration over a 72-h time period. Rats were injected subcutaneously with either 1.2 mg/kg sustained-release formulation (Bup-SR), 0.2 mL/kg buprenorphine HCl (Bup-HCl), or an equivalent volume of sustained-release vehicle and tested in a thermal nociception model or a surgical postoperative pain model. In both models, Bup-SR showed evidence of providing analgesia for 2 to 3 d. Thermal latency response in rats that received the sustained-release formulation increased 28.4% and 15.6% compared with baseline values on days 1 and 2, respectively. Rats with a unicortical tibial defect and treated with Bup-SR showed similar willingness to bear weight on the hindlimbs as did negative-control animals (no surgery), demonstrated by counting vertical raises; rats treated with Bup-HCl had significantly fewer vertical raises than did control rats for 5 d after surgery. Plasma concentrations of buprenorphine remained over 1 ng/mL for 72 h after a single dose of Bup-SR. Taken together, the results indicate that this formulation of buprenorphine may be a viable option for treating postsurgical pain in laboratory rats.